Project Grant HT94252510373
Award Date
6/1/25
Completion Date
5/31/29
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award of $1,789,999.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, is funding a novel approach to increase fetal and embryonic hemoglobins for the treatment of sickle cell anemia. The project is being conducted by Brigham & Women's Hospital Inc., a prominent academic medical center and research institution affiliated with Harvard Medical School. The research aims to develop innovative...
The U.S. Defense Health Agency awarded a $3,292,001.00 Project Grant to Albert Einstein College of Medicine in Bronx, NY for the "Production of Cultured Red Blood Cells for Sickle Cell Disease Patient Support" under the Military Medical Research and Development (CFDA 12.420) federal grant program. This grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The project aims to conduct research and...
This $1,016,449.00 Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports single-cell studies of immune-mediated injury and immunoregulation in human vascular composite allograft (VCA) rejection, with a performance period from August 1, 2024 to July 31, 2027. The award was granted to Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in...
The Defense Health Agency awarded a $682,266 Project Grant to Brigham & Women's Hospital Inc. under the Military Medical Research and Development program (CFDA 12.420) on May 15, 2024. The grant supports research to develop targeted endothelial cell-derived extracellular vesicle nanoparticles for immunotherapy against brain cancer, with a performance period ending on May 14, 2026. As a subsidiary of Partners Healthcare System Incorporated, Brigham & Women's Hospital has extensive...
This $483,548.00 Project Grant was awarded on August 1, 2024 by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports "SINGLE-CELL STUDIES OF IMMUNE-MEDIATED INJURY AND IMMUNOREGULATION IN HUMAN VCA REJECTION" at Brigham & Women's Hospital Inc., a prominent academic medical center and research institution in Boston, Massachusetts. The research funded by this grant aims to advance the understanding of...
The Defense Health Agency awarded a $1,318,799.00 Project Grant to Brigham & Women's Hospital Inc. in Boston, MA on June 15, 2023 under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "THE BRIDGE PROJECT: BROADENING THE REACH OF IMAGING, DIAGNOSTICS, AND GENETIC EVALUATION", will fund research and development to transform healthcare for U.S. military service members and the public through innovative medical solutions for the battlefield and...
The U.S. Department of the Army Medical Command has awarded a $577,383.00 Project Grant to The Children's Hospital Corporation, doing business as Boston Children's Hospital, under the Military Medical Research and Development (CFDA 12.420) federal grant program. This grant, with a performance period from September 1, 2024 to August 31, 2027, will support the hospital's research to develop base editing techniques to improve conditioning and transplantation of bone marrow failure patients. As a...
The federal Project Grant award of $644,400 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support research by Brigham & Women's Hospital Inc. to optimize anti-PD1-based therapy for metastatic renal cell carcinoma. The research aims to transform healthcare for military service members and the general public by advancing innovative approaches to disease prevention, diagnosis, and treatment. The research will be conducted at...
This federal Project Grant award of $1,991,326.00, awarded by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports advanced biomedical research at Beth Israel Deaconess Medical Center, Inc. (Bidmc) aimed at suppressing barrier antimicrobial defenses in the context of trauma. The 3-year grant, with a performance period from September 30, 2024 to September 29, 2027, will enable Bidmc, a prominent academic medical center in...
This $168,042 federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports in vivo targeting research related to TFE3 dimerization partners in translocation renal cell carcinoma at Brigham & Women's Hospital Inc. in Boston, Massachusetts. The award will fund advanced biomedical research focused on developing innovative diagnostic and therapeutic approaches for this specific type of kidney cancer, which is...